R. David Anderson, MD

R. David Anderson, MD, FACC, FSCAI
Associate Professor of Medicine
Director, Interventional Cardiology
Director, Cardiac Catheterization Laboratory

Email: david.anderson@medicine.ufl.edu

TEL: (352) 273-9076
FAX: (352) 846-0314

Academic/Research Interests:

Dr. Anderson has continued interest and participation in clinical trials of device and drug development for both stable coronary artery disease and acute coronary syndromes.  His interests also include the application of advanced interventional techniques including rotational and orbital atherectomy, embolic protection, and thrombectomy in the treatment of both coronary artery and peripheral arterial disease.  Dr. Anderson is involved in clinical trials of novel and interventional-based treatments for resistant hypertension.  He has established a multi-disciplinary clinic for the evaluation and treatment of aortic valve disease to include percutaneous valve therapy.  Dr. Anderson has participated in the design and execution of multiple clinical trials involving the use of angiogenesis growth factors in the treatment of peripheral arterial disease and is actively involved in ongoing clinical trials of cardiac regeneration therapy using stem cells.  He is an active member of the American College of Cardiology, the Florida Chapter of the American College of Cardiology, the American Heart Association, and the Society of Coronary Angiography and Intervention.

Clinical Interests:

Dr. Anderson’s clinical interests include interventional cardiology, peripheral vascular intervention, percutaneous treatment of valvular disease and clinical trial design and execution.

Publications:

Winchester DE, Wen X, Brearley WD, Park KE, Anderson RD, Bavry AA. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. J Am Coll Cardiol. 2011;57:1190-9. 

Moliterno DJ; TENACITY Steering Committee. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. Catheter Cardiovasc Interv. 2011;77:1001-9. 

Khuddus MA, Pepine CJ, Handberg EM, Bairey Merz CN, Sopko G, Bavry AA, Denardo SJ, McGorray SP, Smith KM, Sharaf BL, Nicholls SJ, Nissen SE, Anderson RD. An intravascular ultrasound analysis in women experiencing chest pain in the absence of obstructive coronary artery disease: a substudy from the National Heart, Lung and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Interv Cardiol. 2010;23:511-9. PMC3019081

Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-Dehoff RM, Handberg EM, Pepine CJ. Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension. 2010;55:48-53.

Pepine CJ, Anderson RD, Sharaf BL, Reis SE, Smith KM, Handberg EM, Johnson BD, Sopko G, Bairey Merz CN. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) study. J Am Coll Cardiol. 2010;55:2825-32.

Pearl R, Hassan M, Anderson RD. Left internal mammary artery graft decompression by covered stent treatment of an adjacent saphenous vein graft pseudoaneurysm. JACC Cardiovasc Intervent. 2010;3:688-90.

Garasic JM, Marin L, Anderson RD. Acute evaluation of the Mynx vascular closure device during arterial re-puncture in an ovine model. J Invasive Cardiol. 2009;21:283-5.